207 related articles for article (PubMed ID: 10572111)
21. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
22. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
[TBL] [Abstract][Full Text] [Related]
23. The predictive value of helper T lymphocyte precursor frequencies for graft-versus-host disease and graft-versus-leukaemia effects in allogeneic bone marrow transplantation.
Russell CA; Heilmann C; Madsen HO; Vindeløv LL
Bone Marrow Transplant; 2001 May; 27(9):949-58. PubMed ID: 11436105
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
25. Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor.
Sivula J; Turpeinen H; Volin L; Partanen J
BMC Immunol; 2009 May; 10():24. PubMed ID: 19409109
[TBL] [Abstract][Full Text] [Related]
26. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor.
Lin MT; Storer B; Martin PJ; Tseng LH; Grogan B; Chen PJ; Zhao LP; Hansen JA
Blood; 2005 Dec; 106(12):3995-4001. PubMed ID: 16109775
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation.
Ishikawa Y; Kashiwase K; Akaza T; Morishima Y; Inoko H; Sasazuki T; Kodera Y; Juji T
Bone Marrow Transplant; 2002 Apr; 29(7):569-75. PubMed ID: 11979305
[TBL] [Abstract][Full Text] [Related]
28. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation.
Mullighan C; Heatley S; Doherty K; Szabo F; Grigg A; Hughes T; Schwarer A; Szer J; Tait B; To B; Bardy P
Transplantation; 2004 Feb; 77(4):587-96. PubMed ID: 15084940
[TBL] [Abstract][Full Text] [Related]
29. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.
Lin MT; Storer B; Martin PJ; Tseng LH; Gooley T; Chen PJ; Hansen JA
N Engl J Med; 2003 Dec; 349(23):2201-10. PubMed ID: 14657427
[TBL] [Abstract][Full Text] [Related]
30. Mapping of susceptibility and protective loci for acute GVHD in unrelated HLA-matched bone marrow transplantation donors and recipients using 155 microsatellite markers on chromosome 22.
Kikuchi T; Naruse TK; Onizuka M; Li S; Kimura T; Oka A; Morishima Y; Kulski JK; Ichimiya S; Sato N; Inoko H
Immunogenetics; 2007 Feb; 59(2):99-108. PubMed ID: 17200870
[TBL] [Abstract][Full Text] [Related]
31. Novel HLA-DP region susceptibility loci associated with severe acute GvHD.
Goyal RK; Lee SJ; Wang T; Trucco M; Haagenson M; Spellman SR; Verneris M; Ferrell RE
Bone Marrow Transplant; 2017 Jan; 52(1):95-100. PubMed ID: 27595289
[TBL] [Abstract][Full Text] [Related]
32. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
33. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.
Tseng LH; Lin MT; Hansen JA; Gooley T; Pei J; Smith AG; Martin EG; Petersdorf EW; Martin PJ
Blood; 1999 Oct; 94(8):2911-4. PubMed ID: 10515896
[TBL] [Abstract][Full Text] [Related]
34. [IL-18 single nucleotide polymorphisms in hematologic malignancies with HLA matched sibling donor allogeneic hematopoietic stem cell transplantation].
Cai X; Song A; Wang H; Zhang P; Zhang G; Yang F; Wei J; Ma Q; Yan Z; Jiang E; Huang Y; Yang D; Wang M; He Y; Han M; Feng S
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):215-20. PubMed ID: 24666487
[TBL] [Abstract][Full Text] [Related]
35. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
36. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
Wagner JL; Seidel K; Boeckh M; Storb R
Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
[TBL] [Abstract][Full Text] [Related]
37. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
[TBL] [Abstract][Full Text] [Related]
38. Use of partially mismatched related donors extends access to allogeneic marrow transplant.
Henslee-Downey PJ; Abhyankar SH; Parrish RS; Pati AR; Godder KT; Neglia WJ; Goon-Johnson KS; Geier SS; Lee CG; Gee AP
Blood; 1997 May; 89(10):3864-72. PubMed ID: 9160695
[TBL] [Abstract][Full Text] [Related]
39. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.
Locatelli F; Bruno B; Zecca M; Van-Lint MT; McCann S; Arcese W; Dallorso S; Di Bartolomeo P; Fagioli F; Locasciulli A; Lawler M; Bacigalupo A
Blood; 2000 Sep; 96(5):1690-7. PubMed ID: 10961865
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease.
Elgarten CW; Arnold DE; Bunin NJ; Seif AE
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
